Researchers ordinarily work by deriving testable hypotheses from theories using a deductive process. Hypothesis testing is inherently biased, however, because of the practical requirements of fi nding and publishing positive results. In contrast, ignorance isn't biased. The combination of relevant new technology, suffi cient mastery of the topic to know what is not yet known, and access to patients with rare but informative disorders sets the stage for discoveries about disease mechanisms based on induction from observations. Patient-oriented research is a strength of heart-brain medicine. Patients are a unique scientifi c resource because they tell us the truth. We experience the joy and thrill of a "sparkle of insight" when we realize what they teach.
T
his is a momentous occasion for me, for the extraordinary people in the Clinical Neurocardiology Section at the National Institutes of Health (NIH), and for my family-my wife Minka and son Joey drove all the way from Maryland late last night and early this morning to be here. I thank them publicly here.
THE 'SPARKLE OF INSIGHT' FROM ENLIGHTENED INDUCTION
In these brief comments, as I look back on the road I have taken over the past 40 years carrying out patient-oriented research in heart-brain medicine, I would like to convey a viewpoint instead of dwelling on the presentation of research data.
The idea I wish to convey is that ignorance isn't biased. If you have a hypothesis you want to test, you are inherently biased to fi nd something positive-and, if you are in academic medicine, publishable-in the data you obtain. But if you have the technical capability to measure something no one else can measure, and you have suffi cient mastery of the topic to know what is not yet known, then if you make an observation that you did not predict and if you recognize its signifi cance, you have made a discovery. You have revealed a bit of the truth. You experience the highest joy and thrill a scientist can feel-a "sparkle of insight." When this happens, if you have sense, you stop what you have been doing to pursue that discovery.
Hardly anyone has received a Nobel Prize for testing a theory, but many Nobel Prizes have been awarded for technological advances and for discoveries based on those advances. In my view, discoverers use an enlightened inductive approach at least as much as deduction. They develop new technology that enables key novel measurements, and they keep in mind gaps in knowledge, so that they are ready to appreciate the signifi cance of their observations.
A PERSONAL EXAMPLE
'You have to measure something' Let me share an example of this process by relating a sparkle of insight I had several years ago. When I began working at the NIH, I met with the chief of the Hypertension-Endocrine Branch of the National Heart, Lung, and Blood Institute about the research program I would pursue. After listening patiently to me for many minutes as I spouted about how I was going to test hypotheses derived from the concepts that people with hypertension are "hyper-tense," and that stress causes heart disease, the chief responded, "Well, these ideas are all well and good. But what are you going to measure? You can measure whatever you want, but you have to measure something."
Measure something. I wanted to see if there was hyperactivity of the sympathetic nervous system or excessive sympathetic innervation in hypertension, and I started working on ways to measure sympathetic activity.
The sympathetic nervous system at a glance First I should introduce you to the sympathetic nervous system, which is one of the main effectors by PIONEER AWARD ADDRESS which the brain regulates the heart and blood vessels. It is a key link between the brain and heart. The sympathetic nerves to the heart and other organs do not come directly from the brain but from ganglia, which are clumps of nerve cell bodies strung like pearls on a necklace on each side of the spinal column. This origin outside the central nervous system will be an important fact to keep in mind.
In the heart, the sympathetic nerves travel with the coronary arteries and then dive into the heart muscle from the outside. Sympathetic nerves also enmesh the walls of arteries and arterioles. The arterioles constitute the main determinant of total peripheral resistance to blood fl ow in the body and therefore fi gure prominently in the control of blood pressure. The architectural association between sympathetic nerves and the muscle in the heart and arteriolar walls has enticed hypertension researchers for many decades.
A false start with plasma norepinephrine measurement I developed novel methods for measuring plasma levels of norepinephrine, which is the chemical messenger that the sympathetic nervous system uses in regulation of the circulation, and of adrenaline (epinephrine), which is the well-known and potent "fi ght-or-fl ight" hormone. 1 Applying this technology to patients with high blood pressure led to several publications 2-9 but actually shed more heat than light on the hypothesis of sympathetic hyperactivity as a cause of or contributor to hypertension. In the face of negative data, the theory was qualifi ed-sympathetic hyperactivity might be apparent only in the young, or the thin, or the Caucasian, or the male-but not abandoned.
Insights from visualizing sympathetic nerves in the heart
Then I embarked on a project to visualize sympathetic nerves in the heart, by a new technology called positron emission tomographic (PET) scanning. With several colleagues-including Irwin J. Kopin, Graeme Eisenhofer, Peter Chang, David Hovevey-Zion, Ehud Grossman, and Courtney Holmes-to whom I will always be grateful, I developed a PET imaging agent called 6-[
18 F]fl uorodopamine.
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After injection of 6-[ 18 F]fl uorodopamine into a person's vein, PET scan slices of the chest reveal the sympathetic nerves in the heart (Figure 1 ). The top row of Figure 1 shows where the blood is goingperfusion-in four people, and the bottom row shows the 6-[ 18 F]fl uorodopamine scans in the same people. The horseshoe-shaped structure is the main pumping muscle of the heart, the left ventricular myocardium. The "blob" on the patient's right is the liver. 
GOLDSTEIN
Normally, PET scans using 6-[
18 F]fl uorodopamine look remarkably similar to scans using 13 N-labeled ammonia, a perfusion imaging agent. The fi rst patient I studied with this new technology was a patient with a rare disease called pure autonomic failure (PAF). In PAF, there was already good evidence for a loss of sympathetic nerves throughout the body. Myocardial perfusion in this patient was normal, but there was much less than normal 6-[
18 F]fl uorodopamine-derived radioactivity in the heart muscle. In another uncommon disease, multiple system atrophy (MSA), the perfusion was also normal, and the cardiac sympathetic nerves seemed intact, in line with what was already known about this progressive neurodegenerative disease.
Then I tested a patient who had been thought to have MSA but actually had Parkinson disease (PD) with orthostatic hypotension (a fall in blood pressure each time the person stands up). PD with orthostatic hypotension can be very diffi cult to distinguish from the parkinsonian form of MSA. To my complete surprise, the patient with PD had a remarkable decrease in 6-[ 18 F]fl uorodopa mine-derived radioactivity in the heart muscle. There was normal blood fl ow to the heart muscle, so the 6-[
18 F]fl uorodopamine was being delivered, but there was no evidence of sympathetic nerves in the heart. The scans resembled those in the PAF patient, not the MSA patient.
This fi nding did not arise from a prediction to test a hypothesis. It wasn't long before I tested additional PD patients and found the same unexpected results. 14, 15 Because I was ignorant, I wasn't biased. I felt I had put my fi nger on a piece of the truth, and I had to stop and think about the implications of this discovery. I never did come to test the hypotheses that I had sought out originally to test. Instead, I followed a totally new path, based on the discovery of cardiac sympathetic denervation in PD.
Beyond a brain disease:
Seeing PD as a heart-brain disorder More than 50 neuroimaging studies since our original report have agreed remarkably consistently on the association between PD and loss of sympathetic nerves in the heart; moreover, postmortem pathology studies have amply confi rmed that a profound loss of cardiac sympathetic nerves is characteristic of PD. 16 I have yet to come across a single patient with PD and orthostatic hypotension who has not had cardiac sympathetic denervation, and virtually all patients with PD who do not have orthostatic hypotension seem to have at least partial loss of cardiac sympathetic nerves.
Considering that the source of those nerves is the ganglia, which lie outside the central nervous system, PD must be more than a brain disease and more than a movement disorder. It must also be a disease of the sympathetic nerves in the heart, a form of a dysautonomia, and a heart-brain disorder.
The role of catecholamines:
Another discovery born of unbiased ignorance To appreciate fully the signifi cance of this fi nding, I must mention my favorite chemical family, the catecholamines, whose chemical structures resemble cats (Figure 2) . 17 PD results from a loss of a particular chemical, dopamine, in a particular pathway in the brain; dopa mine is a catecholamine. The other catecholamines in humans are norepinephrine and adrenaline. As noted above, norepinephrine is the chemical messenger of the sympathetic nerves, and adrenaline is the well-known hormone that produces many of the signs of emotional distress.
Almost a half century ago, Hornykiewicz and colleagues made the pivotal discovery that PD features loss of dopamine in the nigrostriatal system in the brain. 18 Given the cardiac sympathetic denervation, PD might be a disease of catecholamine systems both inside and outside the central nervous system-dopamine in the nigrostriatal system, and norepinephrine in the sympathetic nerves of the heart.
Then what of the third catecholamine, adrenaline, in PD? Plasma levels of adrenaline and of its metabolite, metanephrine, are normal in PD, even in patients who have PD and orthostatic hypotension, which involves loss of norepinephrine-producing nerves not only in the heart but in other organs. 19 What is different about the adrenaline-producing cells in the 
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medulla (from the Latin for "marrow") of the adrenal glands atop each kidney? Why aren't these catecholamine-producing cells also lost in PD? I have some ideas in mind but won't go into them here. The point is that the discovery of normal adrenaline-producing cells in PD, despite loss of cells producing the other catecholamines, was not based on my testing a hypothesis. It was a discovery born of ignorance, and because ignorance isn't biased, that discovery points to the truth. Whatever the eventual explanation for the specifi c pattern of catecholamine cell loss in PD, it cannot refute the discovery itself.
HOW DISCOVERIES ARISE: AN APPLIED EXERCISE FOR READERS
Now let's have you, the reader, make a discovery and induce its signifi cance based on what I have tried to teach so far, that discoveries arise from the application of relevant technology and from insights of the prepared mind. Take a look at the scans in the left panels of Figures 3 and 4 . The large red structures in Figure 3 , which look like a sad clown's eyes, correspond to the striatum. The striatum is made up of the putamen, which is like the mascara on the side of the sad clown's eyes, and the caudate, which is like the beady eyes themselves. In the left panel of Figure  4 , the small spots in the midbrain correspond to the substantia nigra, a major site of dopamine-producing neurons in the human brain.
We can see in the right panel of Figure 3 that in PD there is a loss of the ability to store dopamine in the striatum-especially in the putamen, the mascara of the sad clown's eyes. In the right panel of Figure  4 we see that in the brainstem there is a loss of the dopamine-containing nerve cells in the substantia nigra. These scans therefore demonstrate graphically the nigrostriatal lesion characteristic of PD. There is a loss of the nerve cells in the substantia nigra in the midbrain and a loss of the dopamine-containing terminals in the striatum. Now take a look at the scans of these areas in a patient with PAF in Figure 5 . Remember that PAF involves a loss of sympathetic nerves in the heart, just like in PD, but that PAF does not involve parkinsonism. Look at the sad clown's eyes. The mascara is there, of course, because the patient does not have parkinsonism. But now look for the spots in the substantia nigra-they are missing, just as in PD. PAF is a rare disease, and I have only studied several cases with high-resolution PET scanning of the brain, but so far they have all had this unexpected, unpredicted fi nding of loss of dopaminergic neurons in the substantia nigra. 20 What does this pattern mean? If PAF patients have just as much loss of nigral neurons as PD patients do, and if PAF patients do not have parkinsonism, then the movement disorder in PD cannot result from loss of the dopamine neurons in the substantia nigra per se. Instead, the movement disorder in PD seems to come from loss of the dopaminergic terminals in the striatum.
How can PAF patients have normal dopamine terminals in the putamen when the number of dopaminergic 
Normal
Parkinson disease 
Parkinson disease cell bodies is severely reduced? Somehow, PAF patients must be able to sprout new terminals, even as they lose the cell bodies. Maybe if we knew how PAF patients do this, we would have a way to treat or even prevent PD. How do PAF patients maintain normal dopamine terminals as the cell bodies die off? No one knows. Until now, no one thought of asking such a question. No one hypothesized that this discovery would be made, but it was. And because ignorance isn't biased, we have put our fi nger on the truth. By keeping in mind what isn't known, we could see what wasn't there. Now we can begin to think of what to look for next.
SUMMARY AND CONCLUSIONS
Because ignorance isn't biased, if you have the tools to make relevant measurements, if you have suffi cient mastery of the subject to know what isn't known, and if you have access to patients with rare but informative disorders, you can make important discoveries based on inductions from observations. The discoveries that cardiac sympathetic denervation characterizes PD and that parkinsonism does not result from loss of dopamine neurons per se depended crucially on studying patients with a rare disease, PAF. In 1657, William Harvey-the same William Harvey who fi rst described the circulation of the blood and who fi rst pointed out the effects of emotions on the heart-wrote eloquently about the extraordinary power of studying patients with rare diseases: Nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path; nor is there any better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of nature, by the careful investigation of cases of rarer forms of disease. For it has been found in almost all things, that what they contain of use or of application, is hardly perceived unless we are deprived of them, or they become deranged in some way. 
